Chemspace and LabNetwork collaborate to extend access to chemical databases

14 Feb 2019

Collaboration provides drug discovery researchers access to European distribution and local support for library of in-stock and on-demand compounds.

Chemspace and LabNetwork, a WuXi AppTec company, both online marketplaces for chemical compounds used in drug discovery, have entered into a collaboration agreement. Under the agreement, LabNetwork’s products will be available on www.chem-space.com, with distribution and technical support provided by Chemspace for European customers. The collaboration expands the market reach of both companies to pharma and biotech companies.

Chemspace and LabNetwork collaborate to extend access to chemical databases

The Chemspace database encompasses over 100 million unique chemical building blocks, fragments and screening compounds, and is the world’s largest library of purchasable chemicals. The online catalogue includes in-stock and make-on-demand molecules, offering an easy, fast way to search using a broad range of filter options, such as substructure, similarity, and by using various text identifiers.

Use of the Chemspace database is free-of-charge for customers. There are no licence fees for users to review and access the platform. Chemspace invites global chemistry suppliers, ranging from small to large organizations, to upload their catalogues to the site, to provide an efficient solution for buyers when sourcing chemicals.

Dr Yurii Moroz, CEO at Chemspace, commented: “The collaboration with LabNetwork will provide drug discovery scientists, medicinal chemists, and academic researchers access to a vast diversity of high-quality products. We see a lot of synergy in our companies combining forces both from a business perspective and also to improve availability of compounds to the research community. Ultimately to shorten the drug discovery process in the hope of finding better cures for patients, quicker.”

Read More

Related news

Follicum files patent application for new topical formulation for hair loss

Follicum files patent application for new topical formulation for hair loss

30 Apr 2019

Using easy-to-apply cream instead of direct scalp injection would extend patent protection by 8 years.

Read more 
Hovione Technology acquires global rights to new pulmonary inhaler device

Hovione Technology acquires global rights to new pulmonary inhaler device

15 Apr 2019

The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.

Read more 
Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Sterling Pharma to acquire CiVentiChem in the US

Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

Read more 
Catalent expands OptiMelt hot melt extrusion capabilities

Catalent expands OptiMelt hot melt extrusion capabilities

4 Apr 2019

The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.

Read more 
'Drugs from bugs' joint venture

'Drugs from bugs' joint venture

4 Apr 2019

Lonza and Chr. Hansen create a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers.

Read more 
Curcumin and pomegrantes - new hope for Alzheimer’s prevention?

Curcumin and pomegrantes - new hope for Alzheimer’s prevention?

3 Apr 2019

New research at University of Warwick will test how curcumin kick-starts the brain’s cleansing of damaging plaques and cells.

Read more 
MedPharm's appointment with Destiny

MedPharm's appointment with Destiny

28 Mar 2019

Global contract provider to develop new XF-platform drug formulations for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections.

Read more 
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

13 Mar 2019

Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.

Read more 
Envigo launches PATHWAY to enable FIH clinical trials

Envigo launches PATHWAY to enable FIH clinical trials

11 Mar 2019

PATHWAY manages the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers.

Read more